Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
John R. Perfect(Duke University), Elizabeth M. Johnson(Bristol-Myers Squibb (Germany)), Richard N. Greenberg(University of Alabama at Birmingham), Kieren A. Marr(Freedom to Live), B. Dupont(Délégation Paris 5), Thomas J. Walsh(Cornell University), Ana Espinel‐Ingroff, G. Just‐Nübling(Goethe University Frankfurt), Irja Lutsar(University of Tartu), Haran T. Schlamm(Pfizer (United States)), Julián Torre‐Cisneros(Instituto de Salud Carlos III)
Cited by 680
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
|Clinical Infectious Diseases|2005|3k